Elanco Animal Health Incorporated Increase (Decrease) in Other Operating Assets and Liabilities, Net
Elanco Animal Health Incorporated (ELAN) reported Increase (Decrease) in Other Operating Assets and Liabilities, Net of $0 for the 12-month period ending 2023-12-31, per its 10-K filed 2024-02-26.
Discontinued › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInOtherOperatingCapitalNet · last filed 2024-02-26
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for the quarter ending 2019-03-31 was $127.60M, a 20.49% increase year-over-year.
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for the quarter ending 2018-03-31 was $105.90M.
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for fiscal 2023 was $0.00.
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for fiscal 2022 was $0.00.
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for fiscal 2021 was -$9.00M.
- Elanco Animal Health Incorporated increase (decrease) in other operating assets and liabilities, net for fiscal 2020 was $0.00.
| Period end | Increase (Decrease) in Other Operating Assets and Liabilities, Net 3 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 9 month | Increase (Decrease) in Other Operating Assets and Liabilities, Net 12 month |
|---|---|---|---|
| 2023-12-31 | $0.00 10-K · filed 2024-02-26 | ||
| 2022-12-31 | $0.00 10-K · filed 2024-02-26 | ||
| 2021-12-31 | -$9.00M 10-K · filed 2024-02-26 | ||
| 2020-12-31 | $0.00 10-K · filed 2023-03-01 | ||
| 2019-12-31 | $0.00 10-K · filed 2022-02-28 | ||
| 2019-03-31 | $127.60M 10-Q · filed 2019-05-14 | ||
| 2018-09-30 | $83.40M 10-Q · filed 2018-11-08 | ||
| 2018-03-31 | $105.90M 10-Q · filed 2019-05-14 | ||
| 2017-09-30 | -$42.70M 10-Q · filed 2018-11-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| MADRIGAL PHARMACEUTICALS, INC. (MDGL) | United States | $11.859B | -38.17 |
| BIOMARIN PHARMACEUTICAL INC (BMRN) | United States | $11.879B | 151.80 |
| Axsome Therapeutics, Inc. (AXSM) | United States | $10.274B | -66.82 |
| CORCEPT THERAPEUTICS INC (CORT) | United States | $12.804B | 169.10 |
| BridgeBio Pharma, Inc. (BBIO) | United States | $12.947B | -20.72 |
| ARROWHEAD PHARMACEUTICALS, INC. (ARWR) | United States | $9.331B | -42.28 |
| Summit Therapeutics Inc. (SMMT) | United States | $13.071B | -13.21 |
| CYTOKINETICS INC (CYTK) | United States | $9.130B | -11.86 |
| Protagonist Therapeutics, Inc (PTGX) | United States | $8.883B | 95.52 |
| TG THERAPEUTICS, INC. (TGTX) | United States | $8.805B | 19.05 |